Use of Angiotensin Receptor Blockers in Combination Therapy of Patients with Essential Hypertension and Diabetes Mellitus

M.D. Ivanova, N.N. Skalii, D.D. Ivanov

Abstract


The article describes a group of drugs used for comorbidity, the comparative characterization of angiotensin II receptor blockers (ARB) and angiotensin-converting enzyme (ACE) inhibitors, listed on the efficacy and safety data from a representative group of ARBs – azilsartan, presented the results clinical studies on these issues.


Keywords


chronic kidney disease; diabetes mellitus; hypertension; angiotensin II receptor blockers; angiotensin-converting enzyme inhibitors; azilsartan medoxomil

References


Unger T., Culman J., Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence // J. Hypertens. — 1998. — 16 (Suppl. 7). — S3-9.

Suzuki T., Nozawa T., Fujii N., Sobajima M., Ohori T., Shida T., Matsuki A., Kameyama T., Inoue H. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease // Coron. Artery Dis. — 2011 — 22. — P. 352-35.

Zanchetti A., Ruilope L.M. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? // J. Hypertens. — 2002 Nov. — 20(11). — 2099-110.

http://bestpractice.bmj.com/best-practice/monograph/530.html

Robles N.R., Romero B., Fernandez-Carbonero E., Sánchez-Casado E., Cubero J.J. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison // Journal of Renin-Angiotensin-Aldosterone System. —2009 Dec. — Vol. 10, № 4. — 195-200.

Parmley W.W. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection // Am. J. Med. — 1998. — 105 (Suppl. 1A). — 27S-31S.

Husain A. The chymase-angiotensin system in humans: editorial review // J. Hypertens. — 1993. — 11. — 1155-9.

Malacco E., Omboni S., Volpe M. et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study // J. Hypertension. — 2010. — 28. — 2342-50.

Takagi H., Mizuno Y., Niwa M., Goto S.N., Umemoto T. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction // Hypertens. Res. — 2014 May. — 37(5). — 432-7.

Kipnes M.S., Handley A., Lloyd E., Barger B., Roberts A. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension // J. Clin. Hypertens. (Greenwich). — 2015 Mar. — 17(3). — 183-92.

Barrios V., Escobar C. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? // Expert Opin. Pharmacother. — 2013 Nov. — 14(16). — 2249-61.

Sica D., White W.B., Weber M.A., Bakris G.L., Perez A., Cao C., Handley A., Kupfer S. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring // The Journal of Clinical Hypertension. — 2011 July. — 13(7). — 567-72.

Bakris G.L., Sica D., Weber M., White W.B., Roberts A., Perez A., Cao C., Kupfer S. The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure // The Journal of Clinical Hypertension. — 2011 Feb. — Vol. 13, № 2.

Weber M.A., White W.B., Sica D., Bakris G.L., Cao C., Roberts A., Kupfer S. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension // Blood Press. Monit. — 2014 Apr. — 19(2). — 90-7.

Abdelsaid M., Coucha M., Ergul A. Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes // Transl. Res. — 2014 Nov. — 164(5). — 424-32.

Nagata R., Kawabe K., Ikeda K. Olmesartan, an angiotensin II receptor blocker, restores cerebral hypoperfusion in elderly patients with hypertension // J. Stroke Cerebrovasc. Dis. — 2010 May. — 19(3). — 236-40. doi: 10.1016/j.jstrokecerebrovasdis.2009.08.004.

Hye Khan M.A., Neckář J., Cummens B., Wahl G.M., Imig J.D. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat // Cardiovasc. Drugs Ther. — 2014 Aug. — 28(4). — 313-22.

Kosaka S., Pelisch N., Rahman M. et al. Effects of angiotensin II AT 1 receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats // J. Pharmacol. Sci. — 2013. — 121(2). — 95-102.

Takada S., Kinugawa S., Hirabayashi K. et al. Angiotensin II Receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice // J. Appl. Physiol. — 2013, Jan 17.

Saito I., Kario K., Kushiro T. et al. Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the ­HONEST study // Hypertens. Res. — 2013. — 36(2). — 177-82.

Bakris G.L., Sica D., White W.B., Cushman W.C., Weber M.A., Handley A., Song E., Kupfer S. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil // Am. J. Med. — 2012 Dec. — 125(12). — 1229.e1-1229.e10.

Perry C.M. Azilsartan medoxomil: a review of its use in hypertension // Clin. Drug Investig. — 2012, Sep 1. — 32(9). — 621-39.




DOI: https://doi.org/10.22141/2307-1257.0.2.12.2015.75372

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru